Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Salix Pharmaceuticals (NASDAQ:SLXP), a globally diversified pharmaceutical company focused primarily on treating gastrointestinal diseases, rocketed higher by as much as 13% after reporting positive late-stage data for rifaximin (known better as Xifaxan) as a repeat treatment for patients with irritable bowel syndrome with diarrhea, or IBS-D.

So what: According to results from the TARGET 3 study where Xifaxan was administered three-times daily for 14 days to patients, "a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period (Primary Evaluation Period, or PEP) in the Double Blind Repeat Treatment Phase." Xifaxan was also considered well-tolerated and safe in the study which confirmed the efficacy exhibited in TARGET 1 and TARGET 2. Salix believes these results pave the way for a supplemental new drug filing.

In response to this study, research firm Sterne Agee, commented that it should serve as a means to get Xifaxan approved to treat IBS-D and projected Salix's share price could hit $180. That's close to 50% additional upside from yesterday's close.

Now what: In addition to this positive news, Salix also has a big catalyst coming up in two weeks involving the Food and Drug Administration's decision on ruconest, a hereditary angioedema drug that it acquired when it purchased Santarus for $2.6 billion in cash. Chances are probably better than 50-50 that it will be approved as well (at least in my opinion). Things are certainly hitting on all cylinders for Salix. Despite today's run higher, the company's forward P/E still sits at a minuscule 19, which isn't unreasonable considering its annual sales growth estimate over the next five years is near 20%. This is a specialty pharmaceuticals company that very well could continue to rise and I'd have no qualms about you adding it to your watchlist.

Salix may have soared today, but the enormous potential afforded by this product could leave Salix eating its dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.